Procaine butyrate | 136-55-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Procaine butyrate
• 英文别名: butanoic acid;2-(diethylamino)ethyl 4-aminobenzoate
• CAS: 136-55-0
• 化学式: C17H28N2O4
• 分子量: 324.4
• InChiKey: JJCJKGKSHRXGHT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.64
• 重原子数：
  23
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  92.9
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Multi-Layer Tablets and Bioadhesive Dosage Forms
  申请人：Nangia Avinash

  公开号：US20080311191A1

  公开（公告）日：2008-12-18

  Bioadhesives coatings increase the gastrointestinal retention time of orally-ingested medicaments. Certain bioadhesive coatings producing a fracture strength of at least 100 N/m 2 , as measured on rat intestine, when applied to at least one surface of a pharmaceutical dosage form for oral delivery of a drug, result in a gastrointestinal retention time of at least 4 hours in a fed beagle dog model, during which the drug is released from the dosage form. Multi-layer tablets, particularly those including hydrophobic excipients, are useful in administering hygroscopic and/or deliquescent drugs. In addition, varying the amount of drug in multi-layer tablets allows the release rate of the drug to be controlled.

  生物粘合剂涂层可以增加口服药物的胃肠道保留时间。当应用于至少一种药物剂型的表面以口服给药时，产生至少100 N/m²的断裂强度的某些生物粘合剂涂层（在大鼠肠道上测量）可导致在饲养的比格犬模型中至少保留4小时的胃肠道保留时间，在此期间药物从剂型中释放。多层片剂，特别是包括疏水助剂的多层片剂，可用于给予吸湿性和/或易溶性药物。此外，改变多层片剂中药物的量可以控制药物的释放速率。
• Acceptably non-hygroscopic formulation intermediate comprising a hygroscopic drug
  申请人：——

  公开号：US20040197411A1

  公开（公告）日：2004-10-07

  A solid particulate composition is provided comprising a hygroscopic and/or deliquescent drug and at least one non-hygroscopic polymer. The drug and the at least one polymer are in intimate association and the composition is acceptably non-hygroscopic.

  一种固体颗粒组合物由吸湿性和/或潮解性药物和至少一种非吸湿性聚合物组成。药物和至少一种聚合物紧密结合，组合物具有可接受的非吸湿性。
• Solid dispersions comprising a hygroscopic and/or deliquescent drug
  申请人：Trivedi S. Jay

  公开号：US20050013856A1

  公开（公告）日：2005-01-20

  A pharmaceutical composition is provided comprising a drug and a carrier medium, wherein the carrier medium comprisese (a) a matrix forming agent selected from the group consisting of hydroxyethylcelluloses, hydroxypropylcelluloses, hydroxypropylmethylcelluloses, hydroxypropylmethylcellulose phthalates, polyvinylpyrrolidones, polyethylene glycols, polyglycolized glycerides, cyclodextrins, carbomers and combinations thereof, and (b) a filler; and wherein the drug is hygroscopic and/or deliquescent and is dispersed in the carrier medium, and wherein the composition is a solid dispersion and is acceptably non-hygroscopic.

  提供了一种药物组合物，该组合物由药物和载体介质组成，其中载体介质包括：(a) 基质形成剂，该基质形成剂选自羟乙基纤维素、羟丙基纤维素、羟丙基甲基纤维素、羟丙基甲基纤维素邻苯二甲酸酯、聚乙烯吡咯烷酮、聚乙二醇、聚乙二醇化甘油酯、环糊精、卡波姆及其组合组成的组；(b) 填料；其中药物具有吸湿性和/或潮解性，并分散在载体介质中，组合物为固体分散体，具有可接受的非吸湿性。
• Compositions and methods for treating neuropathic sensory loss
  申请人：Galer S. Bradley

  公开号：US20050112183A1

  公开（公告）日：2005-05-26

  The present invention relates to methods of reducing the effects of neuropathically induced negative sensory phenomena (NSP). NSP are manifested as the decreased ability to feel light touch, pain, proprioception, vibration, warmth/heat, and coolness/cold. The NSP are treated by application of an anesthetic. The anesthetic is preferably a benzoic acid-based anesthetic. Specifically, a patch containing about 5% lidocaine may be used. The anesthetic is transdermally administered to a patient suffering from NSP at or near the locus of the negative sensory phenomena.

  本发明涉及减少神经病变引起的负感觉现象（NSP）影响的方法。负感觉现象表现为对轻触、疼痛、本体感觉、振动、温/热和冷/凉的感觉能力下降。治疗 NSP 的方法是使用麻醉剂。麻醉剂最好是苯甲酸类麻醉剂。具体来说，可以使用含有约 5%利多卡因的贴剂。对患有非特异性感觉症状的患者，在其负性感觉现象的部位或附近透皮施用麻醉剂。
• COMPOSITION AND ITS USE FOR TREATING NEUROPATHIC SENSORY LOSS
  申请人：Endo Pharmaceuticals Inc.

  公开号：EP1565173A2

  公开（公告）日：2005-08-24